Trial Profile
Combination Chemotherapy (Methotrexate, L-asparaginase, Idarubicin and Dexamethasone) in Patients With Newly Diagnosed Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 12 Feb 2024
Price :
$35
*
At a glance
- Drugs Dexamethasone (Primary) ; Dexamethasone (Primary) ; Idarubicin (Primary) ; Methotrexate (Primary) ; Recombinant L-Asparaginase-medac (Primary) ; Folinic acid
- Indications Blastic plasmacytoid dendritic cell neoplasm
- Focus Therapeutic Use
- Acronyms LpDessai
- 07 Feb 2024 Planned End Date changed from 1 May 2025 to 1 Nov 2024.
- 07 Feb 2024 Status changed from recruiting to active, no longer recruiting.
- 31 May 2022 Planned End Date changed from 1 May 2022 to 1 May 2025.